The CJC-1295 and ipamorelin stack is built on two reasonably documented peptides and zero studies of the two together. No published or registered trial has tested this specific combination in humans.
The CJC-1295 and ipamorelin stack pairs a long-acting GHRH analog with a selective growth hormone secretagogue, and the logic is the same two-pathway rationale behind every GHRH-plus-secretagogue combination. What makes this version distinct is duration. CJC-1295 with DAC has a half-life measured in days, ipamorelin in minutes, so the two work on very different clocks. The pairing is popular and mechanistically reasonable. It also has no direct human trial behind it.
- CJC-1295 with DAC acts on the GHRH receptor; ipamorelin acts on the ghrelin receptor. Two pathways, one GH pulse [3][4]
- The two-pathway rationale is real: GHRH plus a secretagogue produced a GH response well above the sum of each alone in humans [5]
- That study used GHRP-6, not ipamorelin, so applying its magnitude to this stack is extrapolation [5]
- CJC-1295 with DAC has a half-life of 5.8 to 8.1 days; ipamorelin clears in minutes [1]
- No published or registered trial has tested CJC-1295 plus ipamorelin in humans
- FDA has identified serious adverse events for CJC-1295 and flags ipamorelin as a compounding safety risk [7]
What Each Peptide Contributes
The stack combines two molecules that reach the pituitary from different directions. CJC-1295 is a long-acting GHRH analog. Ipamorelin is a selective secretagogue. Pushing both receptors at once is the reason the combination exists.
CJC-1295, the long-acting GHRH analog
CJC-1295 with DAC is a modified GHRH fragment carrying a group that bioconjugates to serum albumin [3], which is what gives it a multi-day half-life. A single dose raised mean plasma GH 2 to 10-fold for 6 days or more and IGF-1 1.5 to 3-fold for 9 to 11 days, and with repeated dosing IGF-1 stayed above baseline for up to 28 days [1]. Its estimated half-life is 5.8 to 8.1 days [1]. That is the sustained-elevation half of the stack.
One point is often stated wrong: CJC-1295 does not abolish GH pulsatility. A study designed to test it found pulse frequency and magnitude unchanged one week after dosing, while basal GH rose 7.5-fold [2]. Pulses continue at normal size, and the trough between them rises. Whether chronically elevated basal GH matters over years has not been established in humans.
Ipamorelin, the selective secretagogue
Ipamorelin works through the ghrelin receptor and was introduced as the first selective growth hormone secretagogue [4]. In animal models it triggered GH release without raising cortisol or ACTH, unlike GHRP-6 and GHRP-2. It clears quickly, so it contributes a sharp, short pulse rather than sustained elevation. Its selectivity data is from swine and rats, and its only published human efficacy trial, for postoperative ileus, missed its primary endpoint [6].
Why Combine Them
A GHRH analog and a secretagogue act on separate receptors that converge on the same pituitary cells, so stimulating both produces more GH than stimulating either alone. This is measured, not theoretical. In healthy people, GH area under the curve was 686 for GHRH alone, 1787 for the secretagogue alone, and 4111 for the two together, well above the arithmetic sum [5].
That result used GHRH with GHRP-6, not CJC-1295 with ipamorelin. The principle that the two drug classes are supra-additive holds in humans. The specific magnitude for this stack has not been measured, so the multiplier figures on vendor pages trace to marketing rather than to a trial [5].
The Duration Mismatch Is the Real Design Question
This is the part most stacking charts skip. CJC-1295 with DAC sustains GH and IGF-1 elevation for days [1], while ipamorelin produces a pulse and is gone in minutes, closer to sermorelin's roughly 4-minute clearance [11] than to CJC-1295's days. The two are not synchronized.
A short secretagogue pulse layered on top of a multi-day GHRH elevation is a different physiologic pattern from the nightly pulse GH-axis therapy is meant to mimic. Whether that sustained-plus-spike pattern is better or worse than a well-timed nightly pulse has not been tested. It is a fair question to put to a prescriber, and there is no trial answer to give.
| CJC-1295 with DAC | Ipamorelin | |
|---|---|---|
| Receptor | GHRH receptor [3] | Ghrelin receptor [4] |
| Half-life | 5.8 to 8.1 days [1] | Minutes |
| GH effect | Sustained 2 to 10-fold for 6+ days [1] | Sharp short pulse [4] |
| Human efficacy trial | Phase 2 terminated in 2006 [9] | Ileus trial, endpoint missed [6] |
| FDA safety signal | Serious adverse events identified [7] | Flagged as a compounding safety risk [7] |
| WADA status | Prohibited at all times [10] | Prohibited at all times [10] |
The Safety and Regulatory Picture
Both peptides carry regulatory signals that are rarely mentioned at point of sale, and they are not identical.
For CJC-1295, FDA states it has identified serious adverse events including increased heart rate and systemic vasodilatory reaction, and that available clinical data are limited [7]. The only registered patient trial, a Phase 2 study in HIV-associated visceral obesity [9], is recorded as terminated in 2006 with no reason stated in the registry.
For ipamorelin, FDA lists the acetate form among the bulk substances it flags as a compounding safety risk, citing immunogenicity risk and serious adverse events including death with intravenous use for gastric motility [7]. In October 2024, an FDA advisory committee voted 0 in favor and 12 against [8] permitting it for compounding.
Both are named on the 2026 WADA Prohibited List under section S2.2.4 [10], prohibited at all times. Neither is an option for anyone subject to anti-doping testing.
How This Compares to a Sermorelin Stack
The closest alternative most people weigh is sermorelin with ipamorelin, or sermorelin on its own. The trade is dosing convenience against duration of exposure. CJC-1295 allows less frequent injection because it lasts for days [1]. Sermorelin mirrors the natural nightly GH pulse and clears before morning [11], which is the pattern the GH axis evolved around.
No head-to-head trial has compared CJC-1295-plus-ipamorelin against sermorelin-plus-ipamorelin, so the choice comes down to whether you value the convenience of weekly-scale dosing or the closer-to-physiologic nightly pattern. Both stacks share the same missing piece: no published trial of the specific combination.
The Honest Verdict
The CJC-1295 and ipamorelin stack is built on two reasonably characterized peptides and no study of the two together. The two-pathway mechanism is legitimate and supported in humans with different molecules [5]. The individual pieces are documented. The specific combination, its dose ratio, and its duration mismatch are not.
If you pursue it, the discipline is the same as for any GH-axis protocol. Draw a baseline IGF-1 first. Confirm the prescriber is a licensed clinician working from your labs, not a checkout page. Retest IGF-1 at 90 days and treat a result above the age-adjusted range as a reason to reduce dose. A program that dispenses this stack without a baseline draw has skipped the one step that makes it measurable.
CJC-1295 plus ipamorelin is two active peptides on different clocks, which makes a starting IGF-1 and a 90-day retest more important, not less. SystemLabs tests IGF-1 before prescribing and formulates CJC-1295 and ipamorelin on clinical indication, so the protocol is built from your labs rather than a fixed template.
Frequently Asked Questions
What does CJC-1295 and ipamorelin do together?
They stimulate a larger GH release than either alone by acting on two different receptors, the GHRH receptor for CJC-1295 and the ghrelin receptor for ipamorelin [3][4]. In humans, a GHRH analog combined with a secretagogue produced a GH response well above the sum of each separately [5], though that study used GHRP-6 rather than ipamorelin.
Is CJC-1295 and ipamorelin better than sermorelin?
There is no trial comparing them, so any preference is inference. CJC-1295 lasts 5.8 to 8.1 days and allows less frequent dosing [1], while sermorelin clears in about 4 minutes and mirrors the natural nightly GH pulse [11]. Both are usually paired with ipamorelin for the two-pathway effect, and neither combination has a published human trial.
How often do you inject CJC-1295 and ipamorelin?
CJC-1295 with DAC has a multi-day half-life, so it is dosed infrequently, while ipamorelin clears in minutes and is dosed for its short pulse [1][4]. Any specific schedule should come from a prescribing physician working from your IGF-1, since the two peptides act on very different timelines.
Is CJC-1295 and ipamorelin safe?
The individual safety signals are worth knowing. FDA has identified serious adverse events for CJC-1295 including increased heart rate and systemic vasodilatory reaction [7], and lists ipamorelin among bulk substances that may present significant safety risks, with a 0-to-12 advisory committee vote against compounding it [7][8]. The combination itself has no published safety data, and both require a baseline IGF-1 and a 90-day retest to use responsibly.
Is CJC-1295 and ipamorelin FDA approved?
No. Neither is an FDA-approved drug, and both are dispensed as compounded preparations. CJC-1295 has never been approved and appears on FDA's safety-risk compounding page [7]. Ipamorelin has no approved product in any form and was voted down 0 to 12 for compounding by an FDA advisory committee [8].
Can you stack CJC-1295, ipamorelin, and sermorelin?
There is no reason to combine two GHRH analogs. CJC-1295 and sermorelin act on the same GHRH receptor, so pairing them is not additive the way adding a secretagogue is [3]. A considered protocol uses one GHRH analog plus one secretagogue, and the choice between sermorelin and CJC-1295 comes down to dosing frequency.
References
- Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults Journal of Clinical Endocrinology & Metabolism, 2006. PMID: 16352683. https://pubmed.ncbi.nlm.nih.gov/16352683/
- Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog Journal of Clinical Endocrinology & Metabolism, 2006. PMID: 17018654. https://pubmed.ncbi.nlm.nih.gov/17018654/
- Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog Endocrinology, 2005. PMID: 15817669. https://pubmed.ncbi.nlm.nih.gov/15817669/
- Ipamorelin, the first selective growth hormone secretagogue European Journal of Endocrinology, 1998. PMID: 9849822. https://pubmed.ncbi.nlm.nih.gov/9849822/
- Growth hormone (GH) secretion in active acromegaly after the combined administration of GH-releasing hormone and GH-releasing peptide-6 Journal of Clinical Endocrinology & Metabolism, 1994. PMID: 8045963. https://pubmed.ncbi.nlm.nih.gov/8045963/
- Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients International Journal of Colorectal Disease, 2014. PMID: 25331030. https://pubmed.ncbi.nlm.nih.gov/25331030/
- Certain bulk drug substances for use in compounding that may present significant safety risks FDA.gov, Human Drug Compounding, 2026. Content current as of 04/22/2026. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- Summary minutes of the Pharmacy Compounding Advisory Committee meeting, October 29, 2024 FDA Advisory Committee, 2024. PCAC summary minutes. https://www.fda.gov/media/185412/download
- A multicenter, randomized, placebo-controlled, double-blind, phase 2 study to evaluate the efficacy and safety of CJC-1295 administered for 12 weeks in HIV infected patients with HIV associated visceral obesity ClinicalTrials.gov, 2006. NCT00267527, terminated. https://clinicaltrials.gov/study/NCT00267527
- The 2026 Prohibited List: International Standard, section S2.2.4 growth hormone releasing factors World Anti-Doping Agency, 2026. WADA 2026 Prohibited List. https://www.wada-ama.org/en/resources/2026-prohibited-list
- Incorporation of D-Ala2 in growth hormone-releasing hormone-(1-29)-NH2 increases the half-life and decreases metabolic clearance in normal men Journal of Clinical Endocrinology & Metabolism, 1994. PMID: 7962295. https://pubmed.ncbi.nlm.nih.gov/7962295/
